98%
921
2 minutes
20
Background: Recently assisted reproduction techniques are more common, which increases multiple pregnancies and adverse perinatal outcomes. Some authors report increased mortality in multiple pregnancies products obtained by techniques of assisted reproduction vs. conceived spontaneously, although other authors found no significant difference.
Objective: To evaluate mortality rate of multiple pregnancies comparing those obtained by assisted reproduction vs. spontaneous conception.
Patients And Method: Retrospective, observational and comparative study. We included pregnant women with 3 or more products that went to the Unidad Médica de Alta Especialidad No. 23, IMSS, in Monterrey, NL (Mexico), between 2002-2008. We compared the number of complicated pregnancies and dead products obtained by a technique of assisted reproduction vs. spontaneous.
Results: 68 multiple pregnancies were included. On average, spontaneously conceived fetuses had more weeks of gestation and more birth weight than those achieved by assisted reproduction techniques (p = ns). 20.5% (14/68) of multiple pregnancies had one or more fatal events: 10/40 (25%) by assisted reproduction techniques vs. 4/28 (14%) of spontaneous multiple pregnancies (p = 0.22). 21/134 (16%) of the products conceived by assisted reproduction techniques and 6/88 (7%) of spontaneous (p < 0.03) died.
Conclusions: 60% of all multiple pregnancies were obtained by a technique of assisted reproduction and 21% of the cases had one or more fatal events (11% more in pregnancies achieved by assisted reproduction techniques). 12% of the products of multiple pregnancies died (9% more in those obtained by a technique of assisted reproduction).
Download full-text PDF |
Source |
---|
Mol Hum Reprod
September 2025
Department of Obstetrics and Gynecology, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Infertility impacts up to 17.5% of reproductive-aged couples worldwide. To aid in conception, many couples turn to assisted reproductive technology, such as IVF.
View Article and Find Full Text PDFArch Gynecol Obstet
September 2025
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Objective: To investigate adverse pregnancy and delivery outcomes in women with GDMA1 during pregnancies conceived through fertility treatments.
Methods: This population-based retrospective cohort study examined adverse pregnancy and delivery outcomes in pregnancies affected by GDMA1 following fertility treatments compared to those conceived naturally. Women with GDMA1 who conceived via fertility treatments were classified as cases, while those who conceived naturally were designated as controls.
Paediatr Perinat Epidemiol
September 2025
Department of Epidemiology and Occupational Health, McGill University, Montréal, Quebec, Canada.
Background: Studies show that foetal and birthweight-for-gestational age centiles are poor predictors of serious neonatal morbidity and neonatal mortality (SNMM) in univariable models.
Objective: We assessed the predictive performance of multivariable SNMM models based on maternal/pregnancy characteristics, with and without birthweight centiles.
Methods: The study was based on all live births in the United States, 2019-2021, with data obtained from the period live birth-infant death files of the National Center for Health Statistics.
BJOG
September 2025
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Objective: To evaluate whether maternal intake of sugar-sweetened beverages (SSB) and artificially sweetened beverages (ASB) affects medically assisted reproduction outcomes (MAR).
Design: Prospective cohort study.
Settings: Fertility centre at an academic hospital.
Cardiovasc Diabetol
September 2025
Computational Biomedicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as Empagliflozin, are antidiabetic drugs that reduce glucose levels and have emerged as a promising therapy for patients with heart failure (HF), although the exact molecular mechanisms underlying their cardioprotective effects remain to be fully elucidated. The EmDia study, a randomized, double-blind trial conducted at the University Medical Center of Mainz, has confirmed the beneficial effects of Empagliflozin in HF patients after both one and twelve weeks of treatment. In this work, we aimed to assess whether changes in lipid profiles driven by Empagliflozin use in HF patients in the EmDia trial could assist in gaining a better understanding of its cardioprotective mechanisms.
View Article and Find Full Text PDF